The Spectranetics Corporation

SPNC develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads. The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures and Stellarex™ drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart. The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
Type
Public
HQ
Colorado Springs, US
Founded
1984
Size (employees)
960 (est)+8%
The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, US

The Spectranetics Corporation Office Locations

The Spectranetics Corporation has an office in Colorado Springs
Colorado Springs, US (HQ)
9965 Federal Dr

The Spectranetics Corporation Metrics

The Spectranetics Corporation Financial Metrics

Revenue (2016)

$270.8 m

Revenue growth (2015-16), %

10%

Gross profit

$202.5 m

Gross profit margin (2016), %

75%

Net income (2016)

($58.1 m)

Market capitalization (28-Apr-2017)

$1.2 b

Closing share price (28-Apr-2017)

$29.2

Cash (31-Dec-2016)

$57.2 m
The Spectranetics Corporation's current market capitalization is $1.2 b.
The Spectranetics Corporation's revenue was reported to be $270.8 m in FY, 2016 which is a 10% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$158.8 m$204.9 m$246 m$270.8 m

Revenue growth, %

29%20%10%

Cost of goods sold

$41.4 m$51.4 m$62.9 m$68.3 m

Gross profit

$117.5 m$153.5 m$183.1 m$202.5 m

Gross profit Margin, %

74%75%74%75%

Operating expense total

$117.1 m$188.4 m$233.4 m$246.1 m

EBIT

$394 k($37 m)($50.5 m)($43.6 m)

EBIT margin, %

0%(18%)(21%)(16%)

Interest expense

$13.3 m

Pre tax profit

$410 k($41.2 m)($58.7 m)($57.3 m)

Income tax expense

$780 k($322 k)$726 k$787 k

Net Income

($370 k)($40.9 m)($59.5 m)($58.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$128.4 m$95.5 m$84.6 m$57.2 m

Accounts Receivable

Inventories

$2.7 m$8.1 m$8.1 m$7.1 m

Current Assets

$167.8 m$172.3 m$158.3 m$135.5 m

PP&E

$28.3 m$33.8 m$44.7 m$44.8 m

Goodwill

$14.8 m$149.9 m$152.6 m$148.8 m

Total Assets

$217.2 m$467 m$468 m$430.1 m

Accounts Payable

$2.6 m$4.4 m$4.4 m$6.2 m

Current Liabilities

$23.2 m$41.3 m$63.7 m$66.9 m

Additional Paid-in Capital

$284.5 m$298.5 m$313.4 m$332.7 m

Retained Earnings

($94.2 m)($135.1 m)($194.6 m)($252.7 m)

Total Equity

$117 m$74.3 m

Financial Leverage

4 x5.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($370 k)($40.9 m)($59.5 m)($58.1 m)

Depreciation and Amortization

$10.6 m$16.8 m$26.6 m$27.4 m

Accounts Receivable

($2.7 m)($2.7 m)($398 k)

Inventories

($359 k)$497 k$497 k($3.7 m)

Accounts Payable

Cash From Operating Activities

$4.2 m($20.4 m)($59.5 m)

Capital Expenditures

($4.6 m)($6.7 m)($9.5 m)($5.4 m)

Cash From Investing Activities

($11.1 m)($240.7 m)($39.5 m)($5.4 m)

Cash From Financing Activities

$97.3 m$228.2 m$88.2 m$2.4 m

Interest Paid

$41 k$3 m$6.5 m$12.1 m

Income Taxes Paid

$357 k$787 k$327 k$445 k

Free Cash Flow

$8.8 m($13.7 m)($49.9 m)

The Spectranetics Corporation Market Value History

The Spectranetics Corporation Company Life

You may also be interested in